ClinicalTrials.gg
CompletedNCT05754957LIBREXIA-ACSUpdated Jul 6, 2026

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

A Phase 3 interventional study of Milvexian and Placebo in Acute Coronary Syndrome, sponsored by Janssen Research & Development, LLC. Completed at 1,003 sites in 44 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14,194
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Enrollment
7th of 186
14,194 · median 150
Started
2023
with 5 others
Phase 3
40 of 265
1 open now
Registered
247th of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 7th largest by enrollment of the 186 interventional ones that give a count, is one of 6 that started in 2023, is one of 40 in phase 3, and was the 247th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have an index event that meets all 3 of the following criteria within 7 days prior to randomization: a) clinical syndrome consistent with spontaneous cardiac ischemia, b) diagnosis of acute coronary syndrome (ACS) (that is, ST-elevation myocardial infarction [STEMI], non-STEMI, or unstable angina [UA]), c) cardiac biomarker elevation (example, troponin I, troponin T, creatine kinase-MB [CK-MB]) above the as determined by the local laboratory
  • Participants must have at least 2 of the following risk factors:a) age 65 or older, b) diabetes mellitus, c) history of a prior myocardial infarction (MI) (other than index ACS event), d) multivessel coronary artery disease (CAD), e) history of coronary artery bypass graft (CABG) surgery prior to index ACS event, f) history of peripheral artery disease (PAD) or cerebrovascular disease (example, carotid atherosclerosis, intracranial artery stenosis, g) conservative management (that is, no percutaneous intervention [PCI] or CABG after index ACS event), h) Any one or more of the following high-risk angiographic features i) total stent length of greater than (>) 30 millimeters (mm), ii) thrombotic target lesion, iii) bifurcation lesion treated with more than one stent, iv) calcified target lesion treated with atherectomy, v) treatment of obstructive left main or proximal left anterior descending artery for index ACS (or clinical diagnosis of an anterior STEMI)
  • All female participants of must have a negative highly sensitive serum beta-human chorionic gonadotropin (hCG) or urine test at screening
  • A female participant must not be pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half-lives) after the last dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • MI secondary to ischemia due to either increased oxygen demand or decreased supply (Type 2 MI) or periprocedural MI as the index ACS event
  • Planned CABG or staged PCI after randomization
  • Any condition that requires chronic anticoagulation at the discretion of the investigator and/or local guidelines
  • Conditions with a significant increased risk of bleeding (example, bleeding within previous 3 months, known bleeding diathesis, et cetera)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14,194 participants (actual)

Study arms

  • Experimental
    Milvexian

    Participants enrolled within 7 days of an acute coronary syndrome (ACS), who have undergone cardiac catheterization with percutaneous intervention (PCI) or who are being managed conservatively with or without catheterization, and who are receiving antiplatelet therapy standard-of-care (single antiplatelet therapy \[SAPT\] or dual antiplatelet therapy \[DAPT\]) as determined by the investigator will receive milvexian 25 milligrams (mg), orally, twice daily.

    Drug: Milvexian

  • Placebo comparator
    Placebo

    Participants enrolled within 7 days of an ACS, who have undergone cardiac catheterization with PCI or who are being managed conservatively with or without catheterization, and who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) as determined by the investigator will receive placebo orally, twice daily.

    Other: Placebo

Interventions

  • Milvexian will be administered orally.

    Also known as: JNJ-70033093, BMS-986177

  • OtherPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Major Adverse Cardiovascular Event (MACE)

    Time to first occurrence of any component of MACE will be reported. MACE is a composite of cardiovascular (CV) death, myocardial infarction (MI), and ischemic stroke.

    Time frame: Up to 3 years 6 months

Secondary outcomes

  1. Time to the First Occurrence of Major Adverse Vascular Event (MAVE)

    Time to first occurrence of any component of MAVE will be reported. MAVE is a composite of CV death, MI, ischemic stroke, major adverse limb event (MALE), and symptomatic venous thromboembolism (VTE).

    Time frame: Up to 3 years 6 months

  2. Time to the First Occurrence of Composite of All-cause Mortality (ACM), Myocardial Infarction (MI) and Ischemic Stroke

    Time to the first occurrence of composite of ACM, MI and ischemic stroke will be reported.

    Time frame: Up to 3 years 6 months

  3. Time to Cardiovascular (CV) Death

    Time to CV death will be reported.

    Time frame: Up to 3 years 6 months

  4. Time to All-cause Mortality (ACM)

    Time to ACM will reported. ACM will be categorized into CV death, non-CV death, and death due to unknown cause.

    Time frame: Up to 3 years 6 months

07

Study locations

1,003 sites
  • Advanced Cardiovascular, LLC
    Alexander City, Alabama 35010, United States
  • SORRA Research
    Birmingham, Alabama 35203, United States
  • Ascension St. Vincent's Health System
    Birmingham, Alabama 35205, United States
  • IMC-Diagnostic and Medical Clinic
    Mobile, Alabama 36604, United States
  • Cardiology Associates of Mobile Inc
    Mobile, Alabama 36608, United States
  • Mercy Gilbert Medical Center
    Gilbert, Arizona 85297, United States
  • Valleywise Health Medical Center
    Phoenix, Arizona 85008, United States
  • HonorHealth Neurology
    Scottsdale, Arizona 85258, United States
  • Arkansas Heart Hospital
    Little Rock, Arkansas 72211, United States
  • Bakersfield Memorial Hospital
    Bakersfield, California 93306, United States
  • Mission Cardiovascular Research Institute
    Fremont, California 94538, United States
  • Radin Cardiovascular Medical Group
    Newport Beach, California 92663, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • VA Palo Alto Healthcare System
    Palo Alto, California 94304, United States
  • Huntington Hospital
    Pasadena, California 91105, United States
  • The Cardiovascular Center
    Redding, California 96001, United States
  • University Of California San Diego
    San Diego, California 92103, United States
  • San Diego Cardiac Center
    San Diego, California 92123, United States
  • VA San Diego Health Care System
    San Diego, California 92161, United States
  • UCLA
    Santa Monica, California 90401, United States
  • NorthBay Clinical Research, LLC
    Santa Rosa, California 95405, United States
  • Ramin Manshadi, MD
    Stockton, California 95204, United States
  • South Denver Cardiology Associates PC
    Littleton, Colorado 80120, United States
  • Nuvance Health Medical Practices Cardiology Danbury
    Danbury, Connecticut 06810, United States
  • Cardiology Associates of Fairfield County, P.C.
    Stamford, Connecticut 06905, United States
  • George Washington University Medical Center
    Washington D.C., District of Columbia 20037, United States
  • FWD Clinical Research
    Boca Raton, Florida 33434, United States
  • Clearwater Cardiovascular Consultants
    Clearwater, Florida 33756, United States
  • Holy Cross Hospital Inc.
    Fort Lauderdale, Florida 33308, United States
  • Integrative Research Associates
    Fort Lauderdale, Florida 33312, United States
  • University of Florida Health Jacksonville
    Gainesville, Florida 32610-0236, United States
  • Inpatient Research Clinic LLC
    Hialeah, Florida 33014, United States
  • Shands Jacksonville Medical Center Inc dba UF Health Jacksonville
    Jacksonville, Florida 32209, United States
  • Cardiology Partners Clinical Research Institute
    Loxahatchee Groves, Florida 33470, United States
  • Baptist Hospital of Miami
    Miami, Florida 33173, United States
  • Advanced Research for Health Improvement
    Naples, Florida 34102, United States
  • Amavita Clinical Research (Dr. Pedro Martinez-Clark)
    North Miami Beach, Florida 33169, United States
  • South Florida Research Solutions LLC
    Pembroke Pines, Florida 33028, United States
  • Coastal Cardiology Consultants
    Safety Harbor, Florida 34695, United States
  • Cardiovascular Center of Sarasota
    Sarasota, Florida 34239-3513, United States
  • Tampa Cardiovascular Interventions and Research
    Tampa, Florida 33614, United States
  • Interventional Cardiac Consultants
    Trinity, Florida 34655, United States
  • Cardiology Partners Clinical Research Institute 1
    Wellington, Florida 33449, United States
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
  • Atlanta Clinical Research Center
    Cartersville, Georgia 30121, United States
  • Northeast Georgia Heart Center
    Gainesville, Georgia 30501, United States
  • Cardiovascular Consultants of South Georgia LLC
    Thomasville, Georgia 31792, United States
  • Kootenai Medical Center
    Coeur d'Alene, Idaho 83814, United States
  • Insight Hospital and Medical Center Chicago
    Chicago, Illinois 60616, United States
  • Illinois Heart and Vascular Foundation
    Chicago, Illinois 60657, United States
  • Advocate Heart Institute
    Downers Grove, Illinois 60515, United States
  • Clinical Investigation Specialists, Inc.
    Gurnee, Illinois 60031, United States
  • Essential Concepts Research Solutions
    Palos Hills, Illinois 60465, United States
  • OSF HealthCare Cardiovascular Institute
    Peoria, Illinois 61614, United States
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61636, United States
  • Prairie Cardiovascular Consultants, Ltd.
    Springfield, Illinois 62701, United States
  • Carle Foundation Hospital
    Urbana, Illinois 61801, United States
  • Midwest Cardiovascular Research Foundation
    Elkhart, Indiana 46514-2487, United States
  • Northern Indiana Research Alliance
    Fort Wayne, Indiana 46804, United States
  • IU Health Ball Memorial Hospital
    Muncie, Indiana 47303, United States
  • Reid Health
    Richmond, Indiana 47374, United States
  • Health Midwest Ventures Group, Inc d b a HCA MidAmerica Division, LLC
    Overland Park, Kansas 66209, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Norton Cardiovascular Associates
    Louisville, Kentucky 40205, United States
  • Cambridge Medical Trials
    Alexandria, Louisiana 71301, United States
  • Cardiovascular Institute of the South
    Houma, Louisiana 70360, United States
  • Ochsner Clinic And Hospital
    New Orleans, Louisiana 70121, United States
  • Louisiana Heart Center
    Slidell, Louisiana 70458, United States
  • Monroe Research LLC
    West Monroe, Louisiana 71291, United States
  • Eastern Maine Medical Center Northeast Cardiology Associates
    Bangor, Maine 04401, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21231, United States
  • Suburban Hospital
    Bethesda, Maryland 20814, United States
  • Captiol Cardiology Associates
    Lanham, Maryland 20706, United States
  • Shady Grove Office
    Rockville, Maryland 20850, United States
  • Tidal Health Peninsula Regional Inc.
    Salisbury, Maryland 21801, United States
  • Pentucket Medical Associates
    Haverhill, Massachusetts 01830, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • St. Joseph Mercy Oakland
    Bloomfield Hills, Michigan 48302, United States
  • AAMRC
    Flint, Michigan 48504, United States
  • Jackson Heart Clinic
    Jackson, Michigan 39216, United States
  • Sparrow Clinical Research Institute
    Lansing, Michigan 48912-1811, United States
  • St. Luke's Cardiology Associates
    Duluth, Minnesota 55802-2207, United States
  • HealthEast Medical Research Institute
    Saint Paul, Minnesota 55102, United States
  • Mercy Medical Research Institute
    Chesterfield, Missouri 63017, United States
  • The Curators of the University of Missouri on behalf of University of Missouri Health Care
    Columbia, Missouri 65211, United States
  • North Kansas City Hospital
    Kansas City, Missouri 64116, United States
  • Spectrum Clinical Research
    Kansas City, Missouri 64118, United States
  • Cox Health
    Springfield, Missouri 65807, United States
  • Saint Louis University
    St Louis, Missouri 63110, United States
  • Bryan LGH Heart Institute
    Lincoln, Nebraska 68506, United States
  • Methodist Physicians Clinic Heart Consultants
    Omaha, Nebraska 68114, United States
  • University Medical Center of Southern Nevada
    Las Vegas, Nevada 89102, United States
  • Ash Research Clinic
    Brick, New Jersey 08724, United States
  • Englewood Health
    Englewood, New Jersey 07631, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • Atlanticare Regional Medical Center
    Pomona, New Jersey 08240, United States
  • Cardio Metabolic Institute
    Somerset, New Jersey 08873, United States
  • Buffalo General Medical Center
    Buffalo, New York 14203-1154, United States
  • Jamaica Hospital Medical Center
    Jamaica, New York 11418, United States

Showing the first 100 of 1,003 sites across 44 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Gibson CM, Bahit MC, Mehran R, Mehta SR, Lamee RA, Goto S, Weitz JI, Horrow J, Barnathan ES, Harrington RA, Mahaffey KW, Lam CSP, Pieper KS, Johnston SC, Hankey GJ, Plotnikov AN, Li D, Deng H, Steg PG; Librexia ACS Committees and Investigators.. Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS). Am Heart J. 2025 Jul;285:21-28. doi: 10.1016/j.ahj.2025.02.011. Epub 2025 Feb 20. PubMed 39986336 ↗

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Feb 2026, 33 months.

Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 6, 2023
StartActual
Apr 7, 2023
Primary completionActual
Feb 6, 2026
CompletionActual
Feb 6, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05754957
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Apr 7, 2023
Primary completion
Feb 6, 2026
Completion
Feb 6, 2026
Last update
Jul 6, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion